The external prescription amounts for the anticoagulant Lixiana, co-promoted with Daiichi Sankyo, and the antihypertensive drug Sevican (Sevican, Sevican HCT) increased by 12% and 4% year-over ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan Earthquake and the Fukushima Daiichi nuclear disaster. Fourteen years later ...

J.P. Morgan analyst Seiji Wakao maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on March 5 and set a price target ...

AstraZeneca and Daiichi Sankyo also recently won the FDA’s approval for another ADC they are working on together. Datroway, which also carries a topoisomerase I inhibitor but instead targets the TROP2 ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with ...